|
|
|
| Outcomes of patients older than 75 years with non-metastatic prostate cancer |
| Yoshiyasu Amiyaa, Yasutaka Yamadaa, Masahiro Sugiuraa, Makoto Sasakia, Takayuki Shimaa, Noriyuki Suzukia, Hiroomi Nakatsua, Shino Murakamia, Jun Shimazakib
|
a Department of Urology, Asahi General Hospital, Asahi, Japan;
b Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan |
|
|
|
Abstract Objective: Prostate cancer in elderly patients was formerly treated with androgen deprivation therapy. Since the latter of the 1990s new technologies were introduced into treatments, then strategies have varied. We aimed to observe the outcomes of elderly patients treated during transition period and compare each stage with others.
Methods: During 2008 and 2010, 255 patients with prostate cancer older than 75 years were sequentially treated. With exception of patients with bone and/or visceral metastasis, outcomes of 199 patients with localized and locally advanced stages were examined. Complete records were obtained by the end of 2015.
Results: In total, 122 (61%), 28 (14%), 37 (19%) and 12 (6%) of patients were in stages T1c-T2a, T2b-c, T3 and T4, respectively. Patients generally presented with abnormal screening or lower urinary tract symptom. Seventy-one percent of patients received androgen deprivation therapy as monotherapy and 22% of the radiation-treated patients added androgen deprivation therapy. Patients in stage T1c-T2a and T2b-c showed a favorable prognosis. Some cancer death appeared in patients with T3 and T4 during observation periods. Twenty-seven percent of patients died from prostate cancer-independent complications:pneumonia, heart disease, and brain vascular disease. Tendency is similar to that of Japanese elderly male population. No remarkable side effects from androgen deprivation therapy were noticed.
Conclusion: Elderly patients with localized prostate cancer showed favorable prognosis by androgen deprivation therapy with/without radiation, thus efficacy of androgen deprivation therapy is suitable to elderly patients with applicable stages. Prognosis of patients with locally advanced stage is serious and remains to be improved.
|
|
Received: 13 April 2016
Published: 08 May 2017
|
|
Corresponding Authors:
Jun Shimazaki,E-mail address:shimajun@opal.famille.ne.jp
E-mail: shimajun@opal.famille.ne.jp
|
|
|
| [1] |
S. Sfanos Karen,Yegnasubramanian Srinivasan,G. Nelson William,L. Lotan Tamara,Kulac Ibrahim,L. Hicks Jessica,Zheng Qizhi,J. Bieberich Charles,C. Haffner Michael,M. De Marzo Angelo. If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease[J]. Asian Journal of Urology, 2019, 6(1): 10-25. |
| [2] |
Dong Liang,C. Zieren Richard,Xue Wei,M. de Reijke Theo,J. Pienta Kenneth. Metastatic prostate cancer remains incurable, why?[J]. Asian Journal of Urology, 2019, 6(1): 26-41. |
| [3] |
M. Armstrong Cameron,C. Gao Allen. Current strategies for targeting the activity of androgen receptor variants[J]. Asian Journal of Urology, 2019, 6(1): 42-49. |
| [4] |
B. Isaacs William,Xu Jianfeng. Current progress and questions in germline genetics of prostate cancer[J]. Asian Journal of Urology, 2019, 6(1): 3-9. |
| [5] |
V. Fiandalo Michael,T. Gewirth Daniel,L. Mohler James. Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer[J]. Asian Journal of Urology, 2019, 6(1): 50-56. |
| [6] |
Etheridge Tyler,Damodaran Shivashankar,Schultz Adam,A. Richards Kyle,Gawdzik Joseph,Yang Bing,Cryns Vincent,F. Jarrard David. Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier[J]. Asian Journal of Urology, 2019, 6(1): 57-64. |
| [7] |
Chia-Yi Chu Gina,W.K. Chung Leland,Gururajan Murali,Hsieh Chia-Ling,Josson Sajni,Nandana Srinivas,Sung Shian-Ying,Wang Ruoxiang,Boyang Wu Jason,E. Zhau Haiyen. Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics[J]. Asian Journal of Urology, 2019, 6(1): 65-81. |
| [8] |
Dicken Haley,J. Hensley Patrick,Kyprianou Natasha. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled[J]. Asian Journal of Urology, 2019, 6(1): 82-90. |
| [9] |
Xu Lingfan,Chen Junyi,Liu Weipeng,Liang Chaozhao,Hu Hailiang,Huang Jiaoti. Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer[J]. Asian Journal of Urology, 2019, 6(1): 91-98. |
| [10] |
Chen Kenneth,Jack Tay Kae,Mee Law Yan,Aydin Hakan,Ho Henry,Cheng Christopher,Shyi Peng Yuen John. Outcomes of combination MRI-targeted and transperineal template biopsy in restaging low-risk prostate cancer for active surveillance[J]. Asian Journal of Urology, 2018, 5(3): 184-193. |
| [11] |
Chen Shulian,Gao Rang,Li Hong,Wang Kunjie. Management of acquired rectourethral fistulas in adults[J]. Asian Journal of Urology, 2018, 5(3): 149-154. |
| [12] |
Su Jiarui,Jonathan Aslim Edwin,Aydin Hakan,HoonTan Puay,Sun SienHo Henry. A rare case of isolated castrate resistant bilateral testicular metastases in advanced prostate cancer[J]. Asian Journal of Urology, 2018, 5(2): 127-130. |
| [13] |
Per-Anders Abrahamsson. Intermittent androgen deprivation therapy in patients with prostate cancer:Connecting the dots[J]. Asian Journal of Urology, 2017, 4(4): 208-222. |
| [14] |
Graziele Halmenschlager, Ernani Luis Rhoden, Gabriela Almeida Motta, Lucas Sagrillo Fagundes, Jorge Luiz Medeiros Jr, Rosalva Meurer, Cláudia Ramos Rhoden. Testosterone replacement maintains smooth muscle content in the corpus cavernosum of orchiectomized rats[J]. Asian Journal of Urology, 2017, 4(4): 223-229. |
| [15] |
Dingwei Ye, Yiran Huang, Fangjian Zhou, Keji Xie, Vsevolod Matveev, Changling Li, Boris Alexeev, Ye Tian, Mingxing Qiu, Hanzhong Li, Tie Zhou, Peter De Porre, Margaret Yu, Vahid Naini, Hongchuan Liang, Zhuli Wu, Yinghao Sun. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaïve patients with mCRPC in China, Malaysia, Thailand and Russia[J]. Asian Journal of Urology, 2017, 4(2): 75-85. |
|
|
|
|
